Does Medicaid Cover Retatrutide? What's True Now and After FDA Approval
By The RX Index Editorial Team · Last verified October 16, 2026
No. Medicaid does not cover retatrutide right now. It isn't FDA-approved, so it isn't a covered outpatient drug. Eli Lilly plans to ask the FDA for approval in early 2027. Future coverage depends on its approved uses and your state's rules. Medicaid can already cover routine care in a qualifying clinical trial.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
So the full answer to "does Medicaid cover retatrutide?" has three parts. Not today. Maybe later, depending on the use. And one thing Medicaid already pays for: otherwise-covered routine care if you join a qualifying retatrutide study. The table just below shows all three.
This page is for you if you have Medicaid (or help someone who does), your state stopped covering Wegovy or Zepbound for weight loss and you're thinking about waiting for retatrutide, or someone offered you "reta" and said insurance might pay.
It's not the right page if you only have Medicare (see whether CMS programs will cover retatrutide), you have insurance through work (see where retatrutide stands today), or you want price guesses (see retatrutide cost predictions).
Does Medicaid cover retatrutide right now?
No. Retatrutide is an investigational drug, which means it's still in testing and has no FDA approval. Retatrutide does not meet the covered outpatient drug rules for a Medicaid-paid retail prescription. A prescription or prior-authorization request cannot change its unapproved status.
Here's what Medicaid will and won't pay for around retatrutide, as of October 16, 2026.
| What you might want covered | Does Medicaid pay? | Why |
|---|---|---|
| Retatrutide from a pharmacy | No | Retatrutide is not FDA-approved or licensed, so it is not a "covered outpatient drug" eligible for a retail pharmacy claim (Social Security Act §1927(k)(2)). |
| "Compounded" or "research use only" retatrutide | No; consumer sales for human use are unlawful | The FDA says retatrutide cannot be used in compounding under federal law and hasn't been found safe and effective for any condition. |
| Your regular care while you're in a qualifying retatrutide study (doctor visits, labs, treating side effects) | Yes, for otherwise-covered routine care in a qualifying trial | Every state Medicaid program has had to cover these "routine patient costs" since January 1, 2022 (CMS letter SMD #21-005). |
| The study drug itself inside a trial | Not Medicaid | The same federal rule leaves out the investigational drug and research-only tests. Ask the trial team what they provide. |
| Retatrutide through Lilly's expanded access program | Lilly supplies the drug free; other costs are not established | Lilly Medical says it provides the drug at no cost. Ask the treating doctor and plan about visits, labs, and other charges. This is not Medicaid paying for the drug. |
| FDA-approved GLP-1s for type 2 diabetes, Wegovy's heart-risk or liver-disease use, or Zepbound's sleep-apnea use | Generally covered when the drug and patient meet the rules | The weight-loss exclusion does not apply just because a drug also lowers weight. The exact product, medically accepted use, manufacturer rebate participation, and plan rules still matter (§1927, Wegovy label, Zepbound label). |
| FDA-approved GLP-1s for weight loss only, age 21 or older | Your state's choice | Federal law lets states skip drugs "when used for weight loss" (§1927(d)(2)(A)). |
Think of a future retatrutide prescription like a product that first needs permission to reach a store's shelf. Retatrutide hasn't been delivered to the store yet. Until it is, there's nothing on the shelf for your plan to pay for.
One honest limit: no website, including this one, can tell you whether your state will cover retatrutide for weight loss later. Your state can choose whether to cover that use. What we can do is show you the signs that point each way, and what you can get right now.
Start with your state's current GLP-1 policy, then ask your plan about the exact medicine and reason for treatment.
Retatrutide isn't a retail option yet. The GLP-1 path that fits you today depends on your state, your Medicaid plan's drug list, the reason it's prescribed, shot or pill, and your budget. For a broader comparison, The RX Index's Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. Answer a few quick questions about how you plan to pay and your situation. Choose “Use my insurance,” then “Medicaid.” It won't check your Medicaid coverage. Your plan does that.
When could Medicaid start covering retatrutide?
Not before the FDA approves it. Lilly's announced plan is to apply in the first quarter of 2027. Using FDA's usual review goals gives an illustrative decision window of September–November 2027 for priority review or January–March 2028 for standard review. Those are calculations, not confirmed approval or coverage dates.
Getting from today to a Medicaid-paid prescription involves six steps. Some may overlap. Here's where each one stands.
| Step | What has to happen | Status on Oct 16, 2026 | Timing—not a promise |
|---|---|---|---|
| 1. Lilly applies | Lilly files a Biologics License Application (BLA), the formal request for FDA approval | No filing confirmed in the sources checked | Lilly plans Q1 2027 (Lilly, September 29, 2026) |
| 2. FDA decides | FDA approves or doesn't | Not yet | Illustrative: September–November 2027 (priority) or January–March 2028 (standard), using FDA's review goals. No retatrutide priority-review designation was confirmed. |
| 3. The label sets the uses | FDA's label lists what retatrutide is approved to treat | Unknown | Same day as approval |
| 4. It becomes a Medicaid drug | Once licensed, it must meet the covered-outpatient-drug and manufacturer rebate requirements (§1927) | Not yet | No retatrutide payment-start date confirmed |
| 5. Your state applies its rules | Non-weight-loss uses follow federal drug-benefit rules; prior authorization may apply. Weight loss alone may be excluded. | Future rules not confirmed | Varies by state and use |
| 6. Your plan and your paperwork | Your Medicaid plan applies its drug policy and reviews any required prior authorization | Not yet | No individual approval date can be known now |
The math behind step 2: FDA's goal for original BLAs is to review and act on 90% within 6 months for priority review or 10 months for standard review, after a 60-day filing review. A submission during January–March 2027 produces the windows above. FDA can act sooner, ask for more work, or extend review; an action is not necessarily approval.
Approval is permission to sell. It isn't a coverage decision. That's why the next question matters more than the date.
Will Medicaid have to cover retatrutide after it's approved?
It depends on what the FDA approves it for. Federal law lets states skip drugs "when used for weight loss." For covered outpatient drugs from makers in Medicaid's rebate program, states generally must cover medically accepted uses outside the allowed exclusion categories. They can still require prior authorization or a preferred medicine first (§1927).
“Medically accepted” means an FDA-approved use or one supported by certain recognized drug reference books. That rule does not make unapproved retatrutide an off-label retail prescription. Nor does FDA approval guarantee payment for every patient or brand.
So the label is the whole ballgame. Lilly says its trial results can support applications for three uses: obesity, knee osteoarthritis pain, and obstructive sleep apnea (Lilly, July 23, 2026). Here's how Medicaid's rules would likely apply to each.
| If retatrutide is approved for… | What Medicaid's rule says | How sure we are |
|---|---|---|
| Weight loss / obesity, age 21 or older | Your state may leave it out (§1927(d)(2)(A)) | High. This is the statute. |
| Obstructive sleep apnea with obesity | Likely outside the weight-loss exclusion, as with Zepbound's approved sleep-apnea use. The exact label, rebate participation, and plan rules would still matter. | Medium. This is our reading of §1927; no final retatrutide label or coverage policy is confirmed. |
| Knee osteoarthritis pain with obesity | Our reading: a separate knee-pain indication would not be a "weight loss" use, so the weight-loss exception should not by itself block it (§1927). Prior authorization could still apply. | Medium-low. This is our judgment, not a confirmed agency interpretation. |
| Type 2 diabetes | Generally required coverage for approved GLP-1s when the drug-benefit and plan rules are met | High on the general rule. But diabetes is not one of the three uses named in Lilly's July 23 filing statement. |
| Medically necessary care for someone under 21 | Medicaid's under-21 benefit (EPSDT) requires child-specific review of covered types of care needed to correct or improve a condition, even when adult coverage is excluded | High on the general rule. It does not promise a brand or make retatrutide an approved retail medicine. People ages 18–20 are still under 21. |
The diabetes twist
For GLP-1s, diabetes is an established Medicaid door. But Lilly's July 23 statement lists obesity, knee osteoarthritis pain, and sleep apnea, not diabetes, for its planned filings. It describes a separate diabetes trial program. Lilly's September 29 update reports TRIUMPH-2 results in people with type 2 diabetes and obesity or overweight, and repeats the Q1 2027 filing plan. Those results still do not establish the uses FDA will approve.
So the diabetes door may not be the first one to open. Don't assume a diabetes approval comes first. Lilly's own words don't say that.
What prior authorization means
Prior authorization is a permission slip from your Medicaid plan to pay. Your prescriber sends records showing you meet the plan's rules. A pharmacy claim may be rejected until that approval is in place; that is a payment rule, not permission to prescribe or sell an unapproved drug.
Federal law requires a response to a drug prior-authorization request within 24 hours—not necessarily an approval. It also requires at least a 72-hour supply in an emergency while the request is being resolved, except for excluded categories such as drugs used for weight loss (§1927(d)(5)). These rules do not create access to unapproved retatrutide.
A drug being “nonpreferred” or missing from the regular list is not always the same as a weight-loss benefit exclusion. Ask your plan for its prior-authorization or exception process and the written reason for any denial.
Say it's 2028. In this hypothetical, retatrutide has been approved for sleep apnea, and your sleep study and other records meet the actual label and plan rules. Your prescriber would document treatment of sleep apnea, not submit a weight-loss-only request. The real diagnosis and supporting records can change the coverage path—not just a word on the form.
Will my state's Medicaid cover retatrutide for weight loss?
No future retatrutide coverage policy was confirmed in the sources we reviewed. A useful starting point is what your state does today for approved GLP-1s when they're prescribed for weight loss. That tells you what to ask about now—not whether your state will cover retatrutide later.
We started with our September 28, 2026 review and rechecked the documents linked below on October 16. This is a starting point for adult weight-loss-only coverage, not a guarantee for every drug or managed-care plan. Under-21 medical-necessity rules are separate.
| What the state or program document shows | States and limits |
|---|---|
| Covers selected weight-loss GLP-1s, with prior authorization | Delaware fee-for-service, Kansas, Minnesota, North Carolina, Tennessee, Wisconsin. Preferred medicines and approval rules differ; Wisconsin's July 2026 policy does not mean every GLP-1 is covered for adult weight loss. |
| Covers selected medicines, but with tight rules | Michigan, Virginia. The linked policies restrict access to severe cases and require supporting records. |
| Has a documented pathway; implementation of the proposed revision is not confirmed here | Missouri. The April 23, 2026 document is labeled a revision proposal; it is not proof that every proposed change is active. |
| Announced it will join CMS's BALANCE program; launch not confirmed in this check | Indiana. The July 30, 2026 announcement says eligibility and timing will follow as the agreement is finalized. |
| Ended weight-loss-only GLP-1 coverage in the linked program | California, New Hampshire fee-for-service, Pennsylvania (January 1, 2026); South Carolina (December 31, 2025); Utah fee-for-service (June 30, 2026); Massachusetts (July 3, 2026); Rhode Island (October 1, 2026). Other covered uses and under-21 reviews are separate. |
| Current policy could not be rechecked | Mississippi. Its official pharmacy-policy page returned a temporary-site notice rather than the criteria. We have not counted it as confirmed covered or excluded in this check. |
| Everyone else | Not classified in this short table. Check your state's dated row and source in our 50-state Medicaid GLP-1 tracker, then confirm with your plan. |
Some Medicaid members are in a managed-care health plan with its own name; others use fee-for-service, where the state pays providers directly. A managed-care plan's rules can differ from the state's main list, although some states use a shared list. See Medicaid health plan rules if that's you.
Want to know for sure? Call the pharmacy number on your Medicaid card and say:
"Does my plan cover GLP-1 medicines for weight loss right now, and for which uses? When a new drug like retatrutide is approved, who decides whether it gets added?"
Write down the name of the person you spoke with, the date, and the call reference number. Ask for the written drug policy. If your coverage just ended, ask your prescriber about a care plan and check the appeal deadline on the notice; don't wait for retatrutide to become available.
Could the CMS BALANCE Model cover retatrutide on Medicaid?
Not now. BALANCE's current product criteria require an active ingredient approved for weight management, or expected to be by January 1, 2027, plus at least 9.5% average weight loss at an FDA-approved dose. Retatrutide has no approved dose, is not listed, and Lilly's announced filing plan is Q1 2027. CMS says it expects to renegotiate when new drugs reach the market, so a later addition is possible, not promised.
BALANCE is a voluntary program. CMS bargains with drugmakers for lower GLP-1 prices on behalf of state Medicaid programs that sign up. Its published drug list includes all forms of Mounjaro, Ozempic, Rybelsus, and Wegovy, the Zepbound KwikPen, and Foundayo (CMS, page updated Sept 29, 2026). Retatrutide isn't on the list.
CMS allows state participation to begin from May 2026 through January 1, 2027. Our July 31 BALANCE state snapshot could not confirm a publicly executed state agreement; that dated finding is not a current count of participating states. Indiana's July 30 announcement leaves final timing and eligibility to a later update. The CMS page still lists the participant count as “N/A,” which does not establish how many programs are operational.
CMS also says BALANCE won't guarantee coverage for any one person. Ask your own plan whether its weight-loss benefit is active and which medicines it covers.
Can Medicaid help me get retatrutide through a clinical trial?
Medicaid won't pay for investigational retatrutide as the study drug. But since January 1, 2022, federal law has required every state Medicaid program to cover routine care costs for members in qualifying clinical trials. That means the visits, labs, and side-effect care Medicaid would normally cover—not research-only tests or every trial expense.
This is a Medicaid door that can be open before a drug is approved. Here's how it works, from the CMS guidance to states:
- What qualifies: a trial in any phase, for a serious or life-threatening disease or condition, run under an FDA investigational drug exemption (or one of the other federal approvals listed in the rule).
- Who confirms it: your doctor and the trial's lead investigator attest that joining the trial is appropriate for you. The trial must also meet the federal qualifying rules. You don't have to send the full study plan.
- How fast: Medicaid must decide the routine-cost coverage request within 72 hours.
- Where: Medicaid can't deny you because the trial is in another state or outside your plan's network.
One study now listed as recruiting is SYNERGY-Outcomes (NCT07165028). We checked its status on October 16, 2026; the record was updated October 8. It lists sites across many U.S. states. It's for adults 18 and up with a higher-risk form of fatty liver disease called MASLD (metabolic dysfunction-associated steatotic liver disease). Participants are randomly assigned retatrutide, tirzepatide, or a placebo (a look-alike shot with no medicine) and stay in for about 224 weeks, a little over four years, with roughly 25 to 30 visits. The record also describes an optional two-year extension for eligible participants. People with type 1 diabetes or a BMI (body mass index, a weight-for-height measure) under 25 aren't eligible, and other liver-test and medical rules apply.
That's a big commitment, and you have to have the liver condition. It isn't a shortcut for weight loss. But if it fits you, Medicaid's routine-cost rule can help.
Questions to ask the trial site before you go:
- Are you screening new people this week?
- Does this trial count as a qualifying trial for Medicaid routine costs?
- What do you provide at no cost, and what will be billed to Medicaid?
- Who covers travel?
- What are my chances of getting placebo?
Lilly's trial line is 1-877-285-4559. See our retatrutide trial tracker, and confirm local screening with the trial site.
What about Lilly's expanded access program?
Expanded access is a narrow, doctor-requested way to get an unapproved drug outside a study. Lilly says it provides the retatrutide itself at no cost; that does not establish who pays for visits, tests, monitoring, or travel. Its program (NCT07629401) is listed as available and requires all five of these:
- You're 18 or older.
- Your BMI is 35 or higher despite taking the highest available dose of chronic weight-management medicine as prescribed and tolerating it.
- You have two or more serious or life-threatening obesity-related complications for which you are receiving standard care.
- You can't join a retatrutide or similar trial, either because you don't qualify or because no enrolling site is reasonably close.
- You've discussed every standard option with your doctor, including weight-loss surgery.
Your treating doctor has to make the request by calling Lilly at 1-800-545-5979. You can't apply yourself. Meeting the five criteria does not guarantee acceptance: where you live, drug supply, and the individual medical review still matter. A medical reason not to use retatrutide—a contraindication—excludes a patient.
Lilly's instructions also require the physician to arrange FDA authorization, ethics-board approval, and ongoing monitoring. Lilly does not ship directly to patients. Ask your doctor and Medicaid plan which care costs would be billed; the clinical-trial routine-cost rule is not an automatic coverage promise for expanded access. Our retatrutide early access guide has a checklist to bring to your doctor.
What can I get through Medicaid now while I wait?
Several FDA-approved GLP-1s already have Medicaid paths. These include accepted uses for type 2 diabetes, Wegovy to reduce heart risk in adults with established cardiovascular disease and overweight or obesity, and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy injection also has a specific liver-disease use. The exact product, diagnosis, and plan rules still matter; weight-loss-only coverage depends on your state (§1927, Wegovy label, Zepbound label).
Find your row:
| Your situation | Your likely Medicaid path | Read next |
|---|---|---|
| Type 2 diabetes | Approved diabetes medicines under the plan's drug-benefit rules; not automatic payment for any brand | What GLP-1 does Medicaid cover? |
| Adult with established cardiovascular disease plus overweight or obesity | Wegovy's heart-risk use; confirm the exact formulation and plan criteria | Does Medicaid cover Wegovy? |
| Adult with diagnosed moderate-to-severe obstructive sleep apnea plus obesity | Zepbound's sleep-apnea use, subject to the plan's criteria | Does Medicaid cover Zepbound? |
| Adult with MASH, no cirrhosis, and moderate-to-advanced liver scarring (F2–F3) | Wegovy injection has this indication under accelerated approval. MASH is a form of fatty liver disease with inflammation; it is not every fatty-liver diagnosis. | Wegovy label; Medicaid Wegovy guide |
| Weight loss only, age 21 or older | Your state's choice | 50-state Medicaid GLP-1 tracker |
| You'd rather take a pill | Depends on your state and the reason | Does Medicaid cover Foundayo? |
| Under 21 | Medicaid EPSDT review; a separate CHIP plan may have different rules | Does CHIP cover GLP-1s for teens? |
| Medicare and Medicaid together | Prescriptions generally run through Medicare Part D; ask Medicaid about medicines excluded from Medicare | Medicare GLP-1 Bridge for dual eligibles |
| Need a prescriber who takes Medicaid | Varies by provider | GLP-1 providers that accept Medicaid |
Two quick checks help you ask the right questions. First, what condition is your clinician treating? Second, does your plan cover the exact medicine for that use? A BMI of 30 or higher, or 27 or higher with a weight-related condition, may fit an adult weight-management label, but it is not a Medicaid coverage test. (See the BMI chart.) If you do not know your BMI or diagnosis, your clinician can confirm it; you can still ask your plan for its written policy now.
Whether to start a medicine now or wait is your call, made with your clinician. On coverage alone, there is no confirmed retatrutide date to wait for. Check today's options rather than plan around an approval that has not happened.
For a broader comparison of GLP-1 paths and providers, use Find My GLP-1 Path. It asks a few quick questions; it does not diagnose you, check a Medicaid formulary, or decide which condition gets covered. Your Medicaid plan still makes the coverage call.
Check which GLP-1 path fits your situation
Will Medicaid pay for compounded or "research" retatrutide?
No. Retatrutide is not FDA-approved, and FDA says it cannot be used in compounding under federal law. A product sold to consumers as “research” retatrutide is not a covered retail prescription. FDA warns that products sold this way for human use are of unknown quality.
In its August 12, 2026 statement, Lilly said no regulator anywhere had approved a medicine containing retatrutide. The FDA has warned telehealth companies for marketing retatrutide to consumers. It has also warned ingredient sellers for supplying it to compounders, and called out sellers who label GLP-1s "for research purposes" while selling them for people to inject (FDA, Oct 1, 2026). Lilly has filed lawsuits alleging unlawful sales (Lilly, Aug 12, 2026).
Walk away if you see:
- "Compounded retatrutide" or "pharmacy-grade reta"
- "Research use only," sold with dosing instructions
- "Insurance or Medicaid may reimburse you"
If you used something labeled retatrutide and are worried about an exposure or symptoms, call Poison Control at 1-800-222-1222; do not wait until you feel very sick. Call 911 for collapse, a seizure, trouble breathing, or someone who cannot be awakened. Tell your doctor exactly what you took. For more, see compounded retatrutide and how to avoid fake GLP-1 medications.
What we actually verified
Last verified October 16, 2026. For this page, we read the primary sources and dated each check.
| What we checked | Where | Date checked |
|---|---|---|
| Retatrutide's FDA and compounding status | FDA statement (page current as of October 1, 2026) | October 16, 2026 |
| Lilly's filing plan and the three uses named | July 23 release for the three uses; September 29 release repeats the Q1 2027 BLA plan | October 16, 2026 |
| What Medicaid can cover, exclude, and require prior authorization for | Social Security Act §1927, including the rebate, formulary, and medically accepted use rules | October 16, 2026 |
| Medicaid's trial routine-cost rule | CMS SMD #21-005 (updated April 13, 2022) | October 16, 2026 |
| Review-goal timing, not an approval date | FDA PDUFA VII goals; recalculated from a hypothetical Q1 2027 BLA submission | October 16, 2026 |
| Current approved alternatives and under-21 rules | Wegovy label, Zepbound label, and CMS EPSDT guidance | October 16, 2026 |
| Historical national context, not a current state count | KFF's January 2026 review reported 13 fee-for-service programs covering obesity GLP-1s at that time; the state table above uses the linked primary documents | October 16, 2026 |
| BALANCE drug list and program rules | CMS (page updated September 29, 2026); a drug list is not proof of an individual state's launch | October 16, 2026 |
| Recruiting study and expanded-access status | ClinicalTrials.gov records: SYNERGY-Outcomes (updated October 8, 2026) and expanded access (updated August 6, 2026) | October 16, 2026 |
| Expanded-access product cost and request process | Lilly Medical (reviewed August 26, 2026): drug supplied at no cost; other expenses not established | October 16, 2026 |
| State starting lines | Each state or program document linked in the table above; Missouri's proposed revision and Indiana's announcement are labeled. Mississippi's current criteria were unavailable. | October 16, 2026; not a full 50-state re-audit |
| Dual coverage and the savings-card exclusion | Medicare.gov and Lilly's Zepbound savings-card terms | October 16, 2026 |
What we couldn't confirm: an FDA approval date, the final retatrutide label, any future retatrutide coverage policy, a particular reader's trial-cost approval, expanded-access expenses beyond the free drug, Mississippi's current criteria, or a future retatrutide savings program.
What's our judgment, not a rule: that a separate sleep-apnea or knee-osteoarthritis-pain approval would likely sit outside the weight-loss exclusion. We labeled those readings in the table; they do not guarantee coverage of any future request.
This page was not medically reviewed. We didn't buy, take, or test any product.
Frequently asked questions
Is retatrutide FDA-approved?
No. FDA says retatrutide has not been found safe and effective for any condition. Lilly's announced filing plan is the first quarter of 2027; a filing is not approval.
When will Medicaid cover retatrutide?
No date is confirmed. Based on Lilly's Q1 2027 filing plan, FDA's usual review goals would give an illustrative decision window of September–November 2027 with priority review or January–March 2028 with standard review. Neither window promises approval; payment would also depend on the drug-benefit, indication, and plan rules.
Will Medicaid cover retatrutide for weight loss?
Not today. After approval, adult weight-loss-only coverage could still be excluded under §1927(d)(2)(A). Your state's current GLP-1 policy is a starting point, not a promise about retatrutide; under-21 EPSDT review is separate.
Will Medicaid cover retatrutide for sleep apnea or diabetes?
A separate sleep-apnea or diabetes approval would likely create a non-weight-loss coverage path under Medicaid's drug rules, with the final label and plan criteria still to be met. That is our interpretation, not a retatrutide coverage decision. Diabetes was not among the three uses in Lilly's July 23 filing statement.
Can I use a retatrutide savings card with Medicaid?
There's no approved retail retatrutide product, and we found no official retatrutide savings card. Lilly's current Zepbound copay-card terms exclude people enrolled in Medicaid. A copay card and a separate self-pay offer are different programs; do not assume one program's rules apply to the other. See our Zepbound savings card guide.
Does Medicaid pay for retatrutide clinical trials?
Medicaid does not pay for investigational retatrutide itself. It must cover otherwise-covered routine care in a qualifying trial, not research-only costs. CMS requires a coverage decision within 72 hours and says the trial being out of state or outside the plan's network cannot be a reason to deny that care.
Will the BALANCE Model cover retatrutide?
Not now. Retatrutide is not on CMS's BALANCE drug list and has no FDA-approved dose. The initial rules include weight-management approval, or expected approval, by January 1, 2027. CMS expects to renegotiate as new drugs reach the market, but has not confirmed retatrutide coverage.
Can my Medicaid plan cover compounded retatrutide?
No. FDA says retatrutide cannot be used in compounding under federal law. A seller calling it “compounded” or “research” does not turn it into a covered prescription; products sold this way for human use are of unknown quality.
I have Medicare and Medicaid. Which one pays for GLP-1s?
If you have both, prescriptions generally run through Medicare Part D. Medicaid may cover some medicines excluded from Medicare, so ask about the exact drug and use rather than assume every GLP-1 goes through Part D. Neither program covers retail retatrutide today. See our Medicare GLP-1 Bridge guide for dual eligibles.
Can a teenager on Medicaid get retatrutide?
Not as an approved pharmacy prescription. The SYNERGY-Outcomes study and expanded-access program discussed here require age 18 or older, so an 18- or 19-year-old is not excluded by age alone; all other criteria still apply. Someone under 18 should discuss approved options with their clinician. Medicaid's under-21 benefit and separate CHIP rules are not identical.
Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.
Sources
Sources read October 16, 2026. Dates in parentheses identify the source publication or update, not a new policy effective date. State documents are linked beside their rows above; Mississippi's criteria could not be retrieved.
- U.S. Food and Drug Administration — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current Oct 1, 2026)
- Eli Lilly and Company — Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026)
- Eli Lilly and Company — Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (Aug 12, 2026)
- Social Security Administration — Social Security Act §1927, Payment for Covered Outpatient Drugs
- Centers for Medicare & Medicaid Services — SMD #21-005: Mandatory Medicaid Coverage of Routine Patient Costs in Qualifying Clinical Trials (Apr 13, 2022)
- KFF — Medicaid Coverage of and Spending on GLP-1s (Jan 16, 2026)
- Centers for Medicare & Medicaid Services — BALANCE Model (page updated Sept 29, 2026)
- ClinicalTrials.gov — SYNERGY-Outcomes, NCT07165028 (record updated October 8, 2026)
- ClinicalTrials.gov — Pre-approval Expanded Access of Retatrutide, NCT07629401 (record updated Aug 6, 2026)
- U.S. Food and Drug Administration — PDUFA VII Performance Goals
- The RX Index Research — GLP-1 Medicaid Coverage by State (review dated Sept 28, 2026)
- The RX Index Research — BALANCE Model Medicaid Participating States (historical review dated July 31, 2026)
- Lilly Medical — Is there an expanded access program for retatrutide? (reviewed August 26, 2026; confirms the drug is supplied at no cost)
- Novo Nordisk — Wegovy prescribing information (June 2026 revision; formulation-specific indications)
- Eli Lilly and Company — Zepbound prescribing information (August 2026 revision)
- Centers for Medicare & Medicaid Services — Early and Periodic Screening, Diagnostic, and Treatment
- Medicare.gov — Medicaid and Medicare coverage
- Eli Lilly and Company — Zepbound savings and eligibility terms (the commercial copay-card exclusion is distinct from self-pay program terms)
- Poison Control — Emergency and exposure help
- Eli Lilly and Company — TRIUMPH-2 update and Q1 2027 BLA filing plan (September 29, 2026)